Key Insights

Highlights

Treatment Research

2 treatments under study, led by Mas825

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04641442Phase 2Active Not RecruitingPrimary

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Showing all 1 trials

Research Network

Common Treatments

  • Mas8251
  • Placebo1

Active Sponsors

  • Novartis Pharmaceuticals1

Activity Timeline